Bausch & Lomb Teams With Novartis Ophthalmics AG To Co-Promote Bausch & Lomb Retisert(TM)

Published: Feb 09, 2006

ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 9, 2006--Bausch & Lomb (NYSE:BOL) and Novartis Ophthalmics, a business unit of Novartis Pharmaceutical Corp. (NYSE: NVS), will co-promote Bausch & Lomb's patented orphan drug Retisert(TM) (fluocinolone acetonide intravitreal implant) 0.59 mg, in the United States. Retisert is indicated for the treatment of chronic noninfectious posterior segment uveitis.

Back to news